Catalyst Biosciences Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Nassim Usman

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO	24.9%
Permanencia del CEO	8.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	8.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Nassim Usman en comparación con los beneficios de Catalyst Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	US$7m
Dec 31 2022	US$2m	US$595k	-US$8m
Sep 30 2022	n/a	n/a	US$12m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$1m	US$595k	-US$88m
Sep 30 2021	n/a	n/a	-US$87m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$75m
Dec 31 2020	US$1m	US$574k	-US$56m
Sep 30 2020	n/a	n/a	-US$51m
Jun 30 2020	n/a	n/a	-US$48m
Mar 31 2020	n/a	n/a	-US$44m
Dec 31 2019	US$1m	US$525k	-US$55m
Sep 30 2019	n/a	n/a	-US$52m
Jun 30 2019	n/a	n/a	-US$47m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$2m	US$481k	-US$30m
Sep 30 2018	n/a	n/a	-US$25m
Jun 30 2018	n/a	n/a	-US$23m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$2m	US$464k	-US$26m
Sep 30 2017	n/a	n/a	-US$24m
Jun 30 2017	n/a	n/a	-US$22m
Mar 31 2017	n/a	n/a	-US$17m
Dec 31 2016	US$570k	US$453k	-US$17m

Compensación vs. Mercado: La compensación total de Nassim($USD2.39M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD404.18K).

Compensación vs. Ingresos: La compensación de Nassim ha aumentado mientras la empresa no es rentable.

CEO

Nassim Usman (63 yo)

8.3yrs

Permanencia

US$2,392,782

Compensación

Dr. Nassim Usman, Ph.D. serves as a Venture Partner at Morgenthaler Ventures. Dr. Usman is a part of the life sciences team. He joined Morgenthaler as an Entrepreneur-in-Residence in 2005 and has also serv...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Nassim Usman	President	8.3yrs	US$2.39m	sin datos
Augustine Lawlor	Independent Chairman of the Board	17.8yrs	US$91.00k	sin datos
James Wells	Member of Scientific Advisory Board	no data	sin datos	sin datos
Shaun Coughlin	Member of Scientific Advisory Board	no data	sin datos	sin datos
Edwin Madison	Member of Scientific Advisory Board	7.2yrs	US$695.83k	sin datos
Thomas Eastling	Independent Director	less than a year	sin datos	sin datos
Ying Luo	Independent Director	less than a year	sin datos	sin datos
David Ginsburg	Member of Scientific Advisory Board	14.7yrs	sin datos	sin datos
Robert Fletterick	Member of Scientific Advisory Board	14.7yrs	sin datos	sin datos
Guy Salvesen	Member of Scientific Advisory Board	14.7yrs	sin datos	sin datos
Andrea Hunt	Independent Director	6.1yrs	US$50.00k	0.074% $ 13.6k

8.3yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de HGF2 se considera experimentada (8.3 años de antigüedad promedio).

Catalyst Biosciences Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Insufficient new directors

Insider recently sold €289k worth of stock

Insider recently sold €513k worth of stock

Insider recently bought €891k worth of stock

Catalyst Biosciences, Inc., Annual General Meeting, Aug 15, 2022

Recent updates

Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in a reverse merger transaction.

Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.

Catalyst Biosciences Announces Update on Letter from Nasdaq Regarding Minimum Bid Price Requirement

Full year 2022 earnings released: US$0.26 loss per share (vs US$2.87 loss in FY 2021)

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Inaugural dividend of US$0.24 per share

Insufficient new directors

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Catalyst Biosciences Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Insider recently sold €289k worth of stock

Insider recently sold €513k worth of stock

Inaugural dividend of US$1.43 per share

Catalyst Biosciences, Inc. Declares Special One-Time Cash Dividend, Payable on September 20, 2022

Catalyst Biosciences, Inc. Announces Dismissal of Jds1 Litigation

Second quarter 2022 earnings released: EPS: US$1.64 (vs US$0.64 loss in 2Q 2021)

Forecast to breakeven in 2022

JEC II Associates, LLC Reaches an Agreement Catalyst Biosciences

JDS1 LLC Issues an Investor Presentation to Shareholders of Catalyst Biosciences Inc

JDS1, LLC Provides Information to the Shareholders

JEC II Associates Engages in Discussions with Catalyst Biosciences

Insider recently bought €891k worth of stock

JDS1, LLC Provides Information to the Shareholders

Catalyst Biosciences, Inc., Annual General Meeting, Aug 15, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.79 loss in 1Q 2021)

JDS1 Files a Complaint against Catalyst Biosciences

JDS1 Provides Information to Shareholders of Catalyst Biosciences

Full year 2021 earnings released: US$2.87 loss per share (vs US$2.93 loss in FY 2020)

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian Singer Sends Letter to Catalyst Biosciences

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$0.73 loss in 3Q 2020)

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.96 loss in 2Q 2020)

Catalyst Biosciences Announces First Patient Screened for CFI Deficiency in Its CB 4332 Screening and Natural History of Disease Studies

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from Russell 3000E Value Index

Catalyst Biosciences, Inc. Announces Initiation of Dosing in the Company's Phase 1/2 Study (MAA-202) of Marzeptacog Alfa

Catalyst Biosciences Announces the Dosing of the First Patient in the Crimson 1 Study, the Company's Phase 3 Registration Trial (Maa-304 - Crimson 1)

Revenue beats expectations

New 90-day high: €6.00

Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

New 90-day high: €5.50

Catalyst Biosciences, Inc. Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

New 90-day high: €5.40

New 90-day low: €3.70

New 90-day low - €4.18

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad